Is mannitol combined with furosemide a new treatment for refractory lymphedema?A case report  

作　　者：Hyeon Seong Kim Jae Young Lee Ji Won Jung Kyu Hoon Lee Mi Jung Kim Si-Bog Park 

机构地区：[1]Department of Rehabilitation Medicine,Hanyang University Hospital,Seoul 04763,South Korea

出　　处：《World Journal of Clinical Cases》2021年第29期8804-8811,共8页世界临床病例杂志

摘　　要：BACKGROUND Mannitol is a hyperosmolar agent and the combination of mannitol and furosemide is a widely used treatment for intracranial pressure control.Considering the hypertonic properties of mannitol to move water out of intracellular spaces,we hypothesized that mannitol combined with furosemide could relieve focal tissue swelling in refractory lymphedema.CASE SUMMARY A 90-year-old female had been diagnosed with intracranial hemorrhage and received a combination of mannitol and furosemide for intracranial pressure control.Independent of the intracranial hemorrhage,she had refractory lymphedema of the left lower extremity since 1998.Remarkably,after receiving the mannitol and furosemide,the patient’s lower extremity lymphedema improved dramatically.After the mannitol and furosemide were discontinued,the lymphedema worsened in spite of complete decongestive therapy(CDT)and intermittent pneumatic compression treatment(IPC).To identify the presumed effect of mannitol and furosemide on the lymphedema,these agents were resumed,and the lymphedema improved again.CONCLUSION The present case raises the possibility that a combination of mannitol and furosemide might be considered another effective therapeutic option for refractory lymphedema when CDT and IPC are ineffective.

关 键 词：LYMPHEDEMA MANNITOL FUROSEMIDE REHABILITATION Intermittent pneumatic compression Case report 

分 类 号：R551.2[医药卫生—血液循环系统疾病]